Recent events
Recent events tied to this brand in public sources.
Back to profile29 entries · Page 1 of 2
2022
FDA approves Opdualag for melanoma
The US Food and Drug Administration approved Bristol Myers Squibb's Opdualag for adult and paediatric patients aged 12 or older with metastatic melanoma or melanoma that cannot be treated with surgery.
2022
Bristol Myers Squibb sues AstraZeneca over cancer-treatment patents
Bristol Myers Squibb sued AstraZeneca in Delaware federal court, alleging that AstraZeneca's use of Imfinzi to treat lung and bladder cancer infringes patents related to Opdivo. Bristol Myers sought monetary damages.
2022
Bristol-Myers Squibb sued AstraZeneca over alleged patent infringement
Bristol-Myers Squibb and E.R. Squibb & Sons filed suit against AstraZeneca entities in the District of Delaware, alleging that marketing durvalumab infringed their patents. The plaintiffs sought damages and an injunction; the source reports allegations, not a court determination.
2022
Pfizer and BMS relaunch the “No Time to Wait” campaign
Pfizer and Bristol Myers Squibb relaunched the “No Time to Wait” campaign promoting Eliquis and encouraging people experiencing possible symptoms of blood clots or related conditions to seek medical attention.
2021
FDA approves Orencia to prevent acute GVHD
The FDA approved abatacept (Orencia, Bristol Myers Squibb) in combination with a calcineurin inhibitor and methotrexate to prevent acute graft-versus-host disease in adults and children aged 2 years or older undergoing stem cell transplantation from an unrelated donor.
2021
Antengene and Bristol Myers Squibb announce clinical trial collaboration
Antengene announced a clinical trial collaboration with Bristol Myers Squibb to evaluate ATG-017 in combination with Opdivo in a Phase 1/2 trial for advanced solid tumors. Antengene will sponsor and fund the study, and Bristol Myers Squibb will provide Opdivo.
2021
Bristol Myers Squibb sues Eugia Pharma over Sprycel patents
Bristol Myers Squibb filed a lawsuit against Eugia Pharma Specialties alleging that Eugia submitted an application to market a generic equivalent of Sprycel before the relevant patents expired. Bristol Myers Squibb seeks injunctive relief and monetary damages.
2021
Evotec and Bristol Myers Squibb expand neuroscience collaboration
Evotec announced that its collaboration with Bristol Myers Squibb was expanded to include a new cell type, triggering a $9 million payment to Evotec. The expansion enables the companies to investigate neurodegenerative diseases using the additional cell type.
2021
WuXi STA completes acquisition of Couvet manufacturing facility
WuXi STA announced that it had completed its acquisition from Bristol Myers Squibb of a drug product manufacturing facility in Couvet, Switzerland. The facility added WuXi STA's first site in Europe and expanded its drug-product manufacturing capacity.
2021
DarwinHealth and Bristol Myers Squibb announce cancer-target research collaboration
DarwinHealth announced a scientific research collaboration with Bristol Myers Squibb called the Novel Cancer Target Initiative to identify novel cancer targets across tumor subtypes. DarwinHealth will provide proprietary drug-database information and analyses; it will receive an upfront payment and may receive development and commercialization milestone payments.
2021
AVEO Oncology and Bristol Myers Squibb sign clinical trial collaboration agreement
AVEO Oncology announced that it had signed a clinical trial collaboration and supply agreement with Bristol Myers Squibb to study Fotivda in combination with Opdivo for patients with advanced renal cell carcinoma. The companies planned a Phase III trial in the United States, Europe and Latin America.
2021
Bristol Myers Squibb and Molecular Templates enter oncology research collaboration
Bristol Myers Squibb and Molecular Templates entered a strategic research collaboration to discover and develop novel therapies against oncology targets. The agreement includes an upfront payment, potential milestone payments and tiered royalties; Molecular Templates will use its ETB platform and Bristol Myers Squibb will receive a license to develop and commercialize ETBs.
2021
FDA approves Breyanzi for certain forms of lymphoma
The FDA approved lisocabtagene maraleucel, marketed by Bristol Myers Squibb as Breyanzi, as a treatment for adults with certain types of non-Hodgkin lymphoma.
2021
Bristol Myers Squibb reports 2020 financial results
Bristol Myers Squibb reported fourth-quarter and full-year 2020 financial results, including full-year revenues of $42.5 billion.
2020
Bristol Myers Squibb completes acquisition of MyoKardia
Bristol Myers Squibb completed its $13.1 billion acquisition of MyoKardia, gaining rights to MyoKardia’s investigational treatment mavacamten and its cardiovascular drug pipeline.
2020
Bristol Myers Squibb raises FY2020 earnings guidance
Bristol Myers Squibb increased its 2020 non-GAAP earnings per share guidance range to $6.25–$6.35 from $6.10–$6.25 and reaffirmed its fiscal 2021 range.
2020
JD Health and Bristol Myers Squibb establish liver disease innovation platform
JD Health and Bristol Myers Squibb jointly established the Liver Disease Innovation Cloud Platform at the China International Import Expo.
2020
Bristol Myers Squibb and insitro agree to develop drugs for ALS and FTD
Bristol Myers Squibb signed a five-year collaboration agreement with insitro to develop drugs for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The agreement provides for an upfront payment and potential milestone payments and sales royalties.
2020
Sensyne Health and Bristol Myers Squibb sign research collaboration
Sensyne Health signed a research collaboration agreement with Bristol Myers Squibb to apply machine learning to rare blood disease research. The initial focus is disease progression and patient stratification in myeloproliferative neoplasms.
2020
IONTAS announces mammalian display technology licensing agreement with Bristol Myers Squibb
IONTAS announced that it had entered into a licensing agreement with Bristol Myers Squibb for IONTAS' proprietary mammalian display technology. IONTAS will receive an upfront payment and work with Bristol Myers Squibb to establish the platform at its facilities; the agreement also provides for maintenance fees, development milestone payments and royalties on antibodies derived from the platform.